Xlife Sciences

Update in progress

XLS.SW (Swiss)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Xlife Sciences AG develops and commercializes life sciences projects across technology platforms, biotechnology/therapies, medical devices, and AI/digital health. The company identifies new therapies and biomarkers from human genetic data, manufactures active pharmaceutical ingredients for humans and animals, and offers clinical research services. It bridges R&D with healthcare markets, supports researchers and entrepreneurs, and pursues kidney-disease biomarkers, antibody-drug conjugates, microfluidic antibody screening, and Neuromex for early neurological disease detection.Founded in 2019, based in Zurich, Switzerland.

Company score

Sentiment: 0.37; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.14; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.21; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.23; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive